LVTX - LAVA Therapeutics GAAP EPS of -$0.57 revenue of $2.64M April, 11 2023 07:32 AM LAVA Therapeutics N.V. 2023-04-11 07:32:24 ET LAVA Therapeutics press release ( NASDAQ: LVTX ): Q4 GAAP EPS of -$0.57. Revenue of $2.64M (+146.7% Y/Y). For further details see: LAVA Therapeutics GAAP EPS of -$0.57, revenue of $2.64M